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GeneThe in vivo study of receptor binding potential in the human brain ismade possible by positron emission tomog-
raphy (PET) imaging. Here we review PET studies of neuroreceptor function in mood disorders — speciﬁcally,
major depressive disorder (MDD) and bipolar disorder (BD). We concentrate on the most widely studied recep-
tors of the serotonergic and dopaminergic systems. Speciﬁcally, the serotonin 1A (5-HT1A), serotonin 2A
(5-HT2A), serotonin 1B (5-HT1B), dopamine 1 (D1), and dopamine 2/3 (D2/3) receptors.We also reviewPET studies
of the serotonin transporter (5-HTT), the dopamine transporter (DAT), monoamine oxidase A (MAO-A), and the
muscarinic 2 receptor (M2). On the basis of the PET literature as well as supporting genetic studies, postmortem
data, and preclinical models of depression, and several models of how monoaminergic function is altered in
mood disorders are discussedwith respect to inﬂammation, endocrine dysfunction, depression subtypes, and al-
tered neurocircuitry.
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Positron emission tomography (PET) makes use of the radioactive
decay of positron-emitting nuclides to measure cerebral blood ﬂow,
metabolic activity or protein binding, in vivo. In vivo receptor function
is best represented by the binding potential (BP), deﬁned as the product
of the density of receptors available to bind the radioligand (Bavail) and
the afﬁnity of the radioligand for its receptor (1/KD), where KD is the dis-
sociation constant (Mintun et al., 1984). Stated differently, BP is the ratio
of speciﬁcally bound to free tracer at equilibrium in a region of interest in
the brain. In the context of PET, three different reference concentrations
generally have been used to calculate this ratio and therefore there are
three ways that the term “BP” is used in the PET literature.
The BPF refers to the ratio at equilibrium of the concentration of
speciﬁcally-bound radioligand in the brain to the concentration of
free radioligand in the brain (Innis et al., 2007). In order to estimate
the concentration of the unbound radioligand in the brain, the con-
centration of free radioligand in the plasma is measured from arterial
blood samples obtained during the scan. Here the assumption is that
under conditions of passive diffusion the concentration of free radioligand
in the plasma equals the concentration of free radioligand in the brain.
In practice, however, the free fraction of radioligand in the plasma can-
not always be distinguished from protein-bound radioligand in the
plasma. Thus a secondmethod for assessing the BP involves calculation
of BPP: the ratio of speciﬁcally-bound radioligand in brain tissue to free
plus protein-bound radioligand in plasma at equilibrium (Innis et al.,
2007). In other words, BPP is not corrected for the fraction of the tracer
that is bound to plasma proteins. In mathematical terms, BPP=
CT−CND/CPwhere CT and CND denotemean radioactivity concentrations
in the region of interest and reference region (see below), respectively,
and CP denotes the equilibrium concentration of radiotracer in the
plasma.
The calculation of BPF and BPP necessitates arterial plasma sampling
and tracer kinetic modeling and therefore the non-displaceable BP
(BPND), which approximates BPF and BPP for certain radioligands,
is usually used where possible. BPND is the ratio of free plus
speciﬁcally-bound radiotracer to free plus nonspeciﬁcally bound (non-
displaceable) radiotracer in brain tissue at equilibrium (Innis et al.,
2007). BPND is calculated using a reference region, i.e. a region of the
brain with negligible density of the receptor of interest. Thus BPND is
the ratio of activity in a regionwhere the target receptor protein is abun-
dantly expressed to activity in a control region that is essentially devoid
of the target receptor protein. A limitation of the BPND parameter is that
a group difference can be driven by an abnormality in either the target
tissue or the reference tissue. Here, the assumption is that the non-
displaceable binding does not differ between the experimental and con-
trol subject samples.In addition, the relative contributions of receptor density and re-
ceptor afﬁnity to the BP parameter vary according to whether the ra-
diotracer is an agonist or an antagonist. Antagonists bind with equal
afﬁnity to receptors in both high and low afﬁnity states and thus
largely measure receptor density while agonists bind preferentially
to receptors in the high afﬁnity state and are therefore sensitive to
both receptor density and afﬁnity. The majority of radioligands devel-
oped to date to measure receptor binding in the brain have been an-
tagonists (Table 1).
Another potential measure of receptor or enzyme function is vol-
ume of distribution (VT), which refers to the ratio of the concentra-
tion of the radioligand (at equilibrium) in the brain tissue (CT) to the
concentration of the radioligand in plasma (CP) (Innis et al., 2007).
VT is used as a measure of receptor binding when no adequate refer-
ence region in the brain is available because of the ubiquity of the
receptor under study. Because the total concentration of radioligand
in the brain tissue (CT) is composed of speciﬁcally bound (CS), non-
speciﬁcally bound (CNS) and free radioligand (CFT), the nomencla-
ture VS is used to signify that the volume of distribution reﬂects
the ratio of the speciﬁcally-bound radiotracer in the brain to the
concentration of the radiotracer in the plasma. VS can be regarded
as essentially equivalent to BPF or BPP (Innis et al., 2007).
In this review we focus on PET studies of neuroreceptor function
in mood disorders — speciﬁcally, major depressive disorder (MDD)
and bipolar disorder (BD). We concentrate on the most widely studied
receptors of the serotonergic and dopaminergic systems: the serotonin
1A, serotonin 2A, dopamine 1, and dopamine 2/3 receptors. We also in-
clude studies of the serotonin transporter, the dopamine transporter,
monoamine oxidase A (MAO-A), the serotonin 1B receptor, and the
muscarinic 2 receptor. In the Results section, below,wepresent an over-
view of the ﬁndings for each receptor. In theDiscussion section,we con-
sider the possible reasons for the inconsistencies in the literature
(where they exist) and refer to converging or diverging evidence from
preclinical, postmortem, and genetic studies. Finally, we construct a
simpliﬁed model of the role played by each receptor in affective illness
and construct a heuristic integrated model of neuroreceptor function in
mood disorders.
Methods
Relevant studies were identiﬁed through a MEDLINE search, Na-
tional Library of Medicine, NIH (http://www.pubmed.gov) and
cross-referenced papers in the ﬁeld. Search terms used included the
following: “PET”, “bipolar disorder”, “major depressive disorder”,
“5-HT1A”, “5-HT2A”, “5-HT1B”, “serotonin transporter”, “monoamine
oxidase A”, “dopamine receptor”, and “dopamine transporter”. To
our knowledge, all papers that compared mood disorder subjects to
Table 1
List of commonly used ligands.
Receptor Radioligand Chemical compound Type
5-HT1A [11C]WAY-100635 N-[2-[4-(2-methoxyphenyl)-1-piperazinyl] ethyl]-N-2-pyridinyl-trans-4-ﬂuorocyclo-hexylcarboxamide Antagonist
5-HT1B [11C]P943. R-1-[4-(2-methoxy-isopropyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)benzyl]-pyrrolidin-2-one Antagonist
5-HT2A [18F]Altanserin 3-(2-(4-(4-Fluorobenzoyl)-1-piperidinyl)ethyl)-2,3-dihydro-2-thioxo-4(1H)-quinazolinone Antagonist
5-HT2A [11C]MDL (R)-1-[2-(4-ﬂuorophenyl)ethyl]-(4-(2,3-dimethoxyphenyl)-4-piperidinemethano) Antagonist
5-HT2A [18F]FESP 3-(2-Fluoroethyl)-8-[4-(4-ﬂuorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5] decan-4-one Antagonist
5-HT2A [18F]Setoperone 6-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-5H-thiazolo[3,2a] pyrimidin-5-one Antagonist
5-HTT [11C](+)McN5652 (6S,10bR)-1,2,3,5,6,10b-hexahydro-6-[4-(methylthio)phenyl]-pyrrolo[2,1-a] isoquinoline Antagonist
5-HTT [11C]DASB 3-Amino-4-[[2-[(dimethylamino) methyl] phenyl]thio]benzonitrile Antagonist
D1 [11C]SCH 23390 8-Chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol Antagonist
D1 [11C]NNC-112 8-Chloro-7-hydroxy-3-methyl-5-(7-benzofuranyl)-2,3,4,5-tetrahydro-IH-3-benzazepine Antagonist
D2/D3 [11C]Raclopride 3,5-Dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl] methyl]-2-hydroxy-6-methoxybenzamide Antagonist
D2/D3 [18F]Fallypride Benzamide, 5-(3-ﬂuoropropyl)-2,3-dimethexy-N-[(2S)-1-(2-propenyl)-2-pyrrolidinyl]methyl Antagonist
D2/D3 [11C]FLB-457 5-Bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl] methyl]-2,3-dimethoxybenzamide Antagonist
D2/D4 [11C]NMSP 8-[4-(4-Fluorophenyl)-4-oxobutyl]-2-methyl-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one Antagonist
DAT [11C]CFT [N-methyl-11C]-2-b-carbomethoxy-3-b-(4-ﬂuorophenyl)-tropane Antagonist
DAT [11C]RTI-32 (–)-2β-Carbomethoxy-3β-(4-tolyl)tropane Antagonist
MAO-A [11C]Harmine 7-Methoxy-1-methyl-9H-[3,4-b]indole Antagonist
M2 [18F]FP-TZTP 3-(3-(3-Flouropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine Agonist
51J.B. Savitz, W.C. Drevets / Neurobiology of Disease 52 (2013) 49–65healthy controls using PET were included in the review. Single photon
emission computerized tomography (SPECT) studies were not included
in this review. Compared with SPECT, PET has modestly higher spatial
resolution, and markedly greater sensitivity (i.e. signal-to-noise ratio)
(Rahmim and Zaidi, 2008). Moreover, the number of radioligands avail-
able for assaying molecular targets of interest is substantially larger for
PET.Results
Serotonin 1A
The serotonin 1A (5-HT1A) literature pertaining to mood disorders
is summarized in Table 2. Studies of MDD patients that have used
BPND as a measure of receptor function have consistently found a de-
crease in 5-HT1A receptor binding in the raphe as well as limbic and
cortical regions (Bhagwagar et al., 2004; Drevets et al., 2000, 2007;
Sargent et al., 2000) — although one study of late-life depression
reported a reduction in the raphe but not in other regions, Meltzer
et al (2004) and Mickey et al. (2008a) found no difference in BPND
in MDD patients versus healthy controls. Similarly, Hirvonen et al.
(2008a) reported reduced 5-HT1A BPP in the cortex and hippocampus,
but not the raphe of drug-naïveMDDpatients. In addition, amixed sam-
ple of women with post-partum MDD and BD showed reduced BPP in
the subgenual and pregenual anterior cingulate, lateral orbital, and
mesiotemporal cortices (Moses-Kolko et al., 2008). Finally, depressed
patients with BD and MDD subjects with a family history of BD also
had lower 5-HT1A BPND than controls in the raphe and mesiotemporal
cortex (Drevets et al., 1999, 2007). Consistent with these data Nugent
et al. (in press) observed reductions in both the BPF and the BPND in de-
pressed bipolar disordered subjects relative to controls.
In contrast, other researchers, notably the Columbia group, reported
increased 5-HT1A BPF both pre-synaptically and post-synaptically in re-
mitted and depressed patients withMDD (Miller et al., 2009a; Parsey et
al., 2010) as well as in patients with BD (Sullivan et al., 2009). In these
studies the BPND was either unchanged or signiﬁcantly reduced in pa-
tients with mood disorders.
In addition, in patients with temporal lobe epilepsy (TLE) the de-
pression ratings were inversely correlated with 5-HT1A receptor dis-
tribution volume in the hippocampus of Theodore et al. (2007).
While subjects with TLE showed decreased 5-HT1A receptor binding
in the epileptic focus itself, comorbid MDD was associated with a sig-
niﬁcantly more pronounced reduction in 5-HT1A receptor binding in
TLE patients relative both to healthy controls and to non-depressedTLE patients, and extending into limbic brain areas outside the epilep-
tic focus (Hasler et al., 2007). In a later study, the same group replicat-
ed the inverse association between depression ratings and
hippocampal binding (Theodore et al., 2012).
The apparent divergence in ﬁndings in mood disorders is addressed
in the Discussion section, but it is noteworthy that the inconsistency
seen in the literature regarding 5-HT1A receptor binding extends to
PET studies of other neuroreceptor species in primary mood disorders
as well.Serotonin 2A
The serotonin 2A (5-HT2A) literature is summarized in Table 3. The
data are contradictory with increases, decreases and no changes in
5-HT2A binding reported. Because the radioligands, [18F]FESP and
[18F]setoperone also bind to D2 receptors, studies applying these
radioligands are limited to examining the cortex which has a relatively
low concentration of D2 receptors. In contrast, [18F]altanserin shows
good afﬁnity and speciﬁcity for the 5-HT2A receptor (Sadzot et al.,
1995) but produces lipophilic metabolites which necessitate additional
modeling.
In the only [18F]FESP study to date, Messa et al. (2003) found a re-
duction in BPND in anti-depressant drug naïve MDD patients in all cor-
tical regions and the anterior cingulate cortex (ACC). Nevertheless,
many of these patients were taking benzodiazepines at the time of
the study. MDD patients have also been reported to show decreased
[18F]altanserin binding in the orbitoinsular cortex (Biver et al.,
1997) and hippocampus (Mintun et al., 2004). Similarly, using [18F]
setoperone, Attar-Levy et al. (1999) and Yatham et al. (2000) reported
decreased BPND in the frontal cortex, and in the frontal, temporal, pari-
etal and occipital cortices, respectively. In contrast, Meyer et al. (2003)
reported an increase in [18F]setoperone binding in Brodmann's area 9
(BA9) in MDD patients who showed elevations in the personality
trait, “dysfunctional attitude”. In a previous study, the same group had
reported that treatment of MDD with paroxetine decreased [18F]
setoperonebinding in the cortex of 20–30 year-old patients—putatively
a result of the downregulation of 5-HT2A receptors (Meyer et al., 2001a).
Finally, a study with the radioligand, [11C]MDL showed increased BPP in
the frontal, parietal and occipital cortices of remitted MDD patients
(Bhagwagar et al., 2006). Bhagwagar et al. (2006) also replicated the
positive association between dysfunctional attitudes and 5-HT2A recep-
tor BP reported by Meyer et al. (2003). As we discuss below, the con-
ﬂicting results may partially result from the use of medicated subjects
in a number of studies mentioned above.
Table 2
5-HT1A receptor imaging studies in mood disorders.
Study Sample Age Method Presynaptic Postsynaptic
Drevets et al.
(1999)a
12 MDD 35.8±9.7 Simpliﬁed reference tissue model
(cerebellum)
↓ BPND
raphe
(27%)
↓ BPND MTC (42%)
8 HC 35.3±13.5
Sargent et al.
(2000)
15
Unmedicated
MDD
37.7±1.7 Simpliﬁed reference tissue model
(cerebellum)
↓ BPND
raphe
(20%)
↓ BPND MTC ( OFC, dACC, VLPFC, DLPFC
and insula in both MDD groups
20
Medicated
MDD
43.1±14.8
18 HC 36.4±8.3
Bhagwagar et al.
(2004)
14 MDD 48±14.9 Simpliﬁed reference tissue model
(cerebellum)
NS ↓ BPND broad areas of cortex (17%), including ACC,
hippocampus, amygdala, frontomedial cortex18 HC 43.2±13
Meltzer et al.
(2004)
17 MDD 71.4±5.9 Distribution volume by graphical analysis
with plasma input function
↓ BPP raphe
(±38%)
NS
17 HC 70±6.7
Parsey et al.,
(2006b)b
13 MDD
Remitters
39.9±10.4 Distribution volume by compartmental
model with plasma input function
NS ↑ BPP non-remitters: ACC, hippocampus, DLPFC,
VLPFC and other cortical regions
9 MDD Non-
remitters
42.9±14.9
43 HC 38.2±15.0
Drevets et al.
(2007)a
16 MDD 32±10 Simpliﬁed reference tissue model
(cerebellum)
↓ BPND
raphe
(43%)
↓ BPND MTC (26%)
8 HC 32±12
Hirvonen et al.
(2008a)
21 MDD 40.1±9 Two-tissue compartmental model with
cerebellar white matter reference tissue
NS (↓) BPP ↓ (9%–25%) BPP in diverse regions including amygdala,
hippocampus, ACC, and mPFC15 HC 32.6±7.7
Mickey et al.
(2008)
14 MDD 38±11 Distribution volume by graphical analysis
with reference tissue
NS NS
17 HC 34±12
Moses-Kolko et al.
(2008)
9 PPD 26.9±7.9 Simpliﬁed reference tissue model
(cerebellum)
NS (↓ 10%) ↓ BPND (20%–28%) sgACC, pgACC, MTC; OFC
7 HC 33.0±3.9
Miller et al.
(2009a)b
15 rMDD 31.8±10.9 Distribution volume by compartmental
model with plasma input function
↑ BPF ↑ BPF
13 MDD 35.9±12.3 ↓ BPND ↓ BPND
51 HC 37.4±14.5 NS BPP NS BPP
Sullivan et al.
(2009)
32 BD 38.4±9.7 Distribution volume by compartmental
model with plasma input function
↑ BPF in
males
↑ BPF in males (29-50%) in diverse regions including amygdala,
hippocampus, ACC, mPFC, OFC, and insula NS (BPND)
47 HC 38.1±14.7 Raphe
(102%)
NS (BPND)
Parsey et al.
(2010)
22 MDD 40.6±13.1 Distribution volume by compartmental
model with plasma input function
↑ BPF ↑ BPF
9 HC 37.4±14.4 ↑ VT ↑ VT
↓ BPND ↓ BPND in diverse regions including amygdala, hippocampus, ACC,
mPFC, OFC, and insula
Sargent et al.
(2010)
8 BD 45±8 Simpliﬁed reference tissue model
(cerebellum)
NS NS
8 HC 49±8
Note: all studies used the radioligand, [carbonyl-11C]WAY-100635. ACC = anterior cingulate cortex; BD = bipolar disorder; DLPFC = dorsolateral prefrontal cortex; HC = healthy
control; MDD=major depressive disorder; mPFC=medial prefrontal cortex; MTC=mesiotemporal cortex; NA= not applicable; NR= not reported; NS= not signiﬁcant; OFC=
orbitofrontal cortex; pgACC = pregenual ACC; PPD = postpartum depression; rMDD = remitted MDD and VLPFC = ventrolateral prefrontal cortex.
a Samples overlapped between these studies.
b Samples overlapped between these studies.
Table 3
5-HT2A receptor imaging studies in mood disorders.
Study Sample Age Medication status Radioligand Method Result
Biver et al.
(1997)
8 MDD 48±10 Unmedicated
10+days
[18F]altanserin Ratio model during
equilibrium
↓ BP right orbitoinsular
cortex22 HC 38±12
Attar-Levy et al.
(1999)
7 MDD 40±11 Unmedicated
1+year
[18F]setoperone Ratio model during
equilibrium
↓ BP frontal cortex
7 HC 38±10
(Meltzer et al.
(1999)
11 MDD 65±6 Unmedicated [18F]altanserin Distribution volume
by graphical analysis with
plasma input function
NS
10 HC 70±5
Meyer et al.
(1999)
14 MDD 32±6 Unmedicated
6+months
[18F]setoperone Ratio model during equilibrium NS
19 HC 32±7
Yatham et al.
(2000)
20 MDD 40±10 Unmedicated
2+weeks
[18F]setoperone Ratio model during equilibrium ↓ BPND in all regions of the cortex
20 HC 38±13
Messa et al.
(2003)
19 untreated MDD 39 Naïve/SSRI [18F]FESP Binding index (the ratio of tracer
uptake in cortex relative to that
in cerebellum)
↓ BPND in naïve MDD frontal,
temporal, occipital
cortices, + ACC
15 treated MDD 37
20 HC 36
Meyer et al.
(2003)
22 MDD 18–44 Unmedicated
4+weeks
[18F]setoperone Ratio model during equilibrium ↑ BP in BA9 in MDD with high
dysfunctional attitude22 HC
Mintun et al.
(2004)
46 MDD 50±6 Unmedicated for
4+weeks
[18F]altanserin Distribution volume by compartmental
model with plasma input function
↓ VT in hippocampus. Trend
perigenual ACC29 HC 46±15
Bhagwagar et al.
(2006)
20 remitted MDD 39±12 Unmedicated
6+months
[11C]MDL Distribution volume by graphical analysis
with plasma input function
↑ BPP frontal, parietal, occipital cortex
20 HC 43±14
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Table 4
5-HTT imaging studies in mood disorders.
Study Sample Age Medication status Radioligand Method Result
Ichimiya et al.
(2002)
7 MDD 44.1±13.5 Unmedicated
6+weeks
[11C]
(+)McN5652
Graphical reference
tissue model
(cerebellum)
↑ BPND in thalamus
in patients
(22%) but not
midbrain
6 BD 41.7±8.8
21 HC 42.3±14.5
Meyer et al.
(2004)
20 MDD 35±11 Unmedicated
3+months
[11C]DASB Graphical reference tissue
model (cerebellum)
NS
20 HC 35±11
Reivich et al.
(2004)
4 MDD 22–56 Unmedicated
ﬁve elimination half-lives
of drug
[11C]
(+)McN5652
Distribution volume by
compartmental model with
plasma input function
↑ BPP left frontal cortex,
right cingulate cortex4 HC 23–59
Cannon et al.
(2006b)
18 BD 30±9 Unmedicated
3+weeks
[11C]DASB Multilinear reference
tissue model (cerebellum)
↑ BPND in thalamus, dorsal
cingulate cortex, mPFC
and insula
↓ BP in raphe
37 HC 32±9
Parsey et al.
(2006a)
25 MDD 38.0±13.4 Unmedicated
2+weeks
[11C]
(+)McN5652
Distribution volume by
graphical analysis with
plasma input function
↓ BPP in amygdala (20%) and
midbrain (20%) in AD-naive
MDD sample
43 HC 38.8±15.9
Bhagwagar et al.
(2007)
24 Remitted MDD 38.9±11.9 Unmedicated
23+months
[11C]DASB Distribution volume by
graphical analysis with
plasma input function
NS
24 HC 35.7±9.8
Cannon et al.
(2007)
18 MDD 35±8.9 Unmedicated
3+weeks
[11C]DASB Multilinear reference
tissue model (cerebellum)
↑ BPND in thalamus (27%), insula
(15%), anteroventral striatum
(12%), pgACC (16%), PAG (22%)
34 HC 33±8.4
Oquendo et al.
(2007)
18 BD 39.3±16.0 Unmedicated
2+weeks
[11C] (+)McN5652 Distribution volume by
graphical analysis with
plasma input function
↓ BPP (16–26%) in midbrain,
putamen, amygdala, thalamus,
and ACC
41 HC 38.1±9.7
Miller et al.
(2008)
7 MDD remitters 38.9±11.4 Unmedicated
2+weeks
[11C] (+)McN5652 Distribution volume by
graphical analysis
with plasma input function
↓ BPP in non-remitters in
midbrain, amygdala and ACC12 MDD non-remitters 41.7±15.1
41 HC 39.0±16.1
Reimold et al.
(2008)
10 MDD 48.3±9.7 Unmedicated ﬁve
elimination half-lives
of drug
[11C]DASB Multilinear reference
tissue model (cerebellum)
↓ BPND in thalamus
19 HC 44.2±10.1
Frokjaer et al.
(2009)
9 HR 32.2±4.2 Naive [11C]DASB Multilinear reference
tissue model (cerebellum)
↓ BPND in DLPFC (35%)
and trend towards signiﬁcance
in ACC (15%) in HR
11 LR 32.4±5.0
Miller et al.
(2009b)
15 MDD with past trauma 39.1±16.1 Unmedicated
2+weeks
[11C] (+)McN5652 Distribution volume by
graphical analysis with
plasma input function
↓ BPP in anterior cingulate,
hippocampus, amygdala,
putamen, midbrain,
thalamus in abused MDD
13 MDD without trauma 39.2±11.4
43 HC 38.8±15.9
Reimold et al.
(2011)
10 MDD 48.3±9.7 Unmedicated ﬁve
elimination half-lives
of drug
[11C]DASB Multilinear reference
tissue model (cerebellum)
↓ BPND in thalamus, which was
associated with higher cortisol
levels after DEX/CRF
20 HC 44.2±9.8
Selvaraj et al.
(2011)
12 MDD 42.1±11.6 Medication free 4–240 months [11C]DASB Distribution volume by
graphical analysis with
plasma input function
↓ BPND in brain stem, thalamus
↓ BPP in brain stem, thalamus,
caudate, putamen, and ACC
24 HC 42.4±11.4
Note: ACC = anterior cingulate cortex; BD = bipolar disorder; DEX/CRF = dexamethasone/cortisol releasing factor; DLPFC = dorsolateral prefrontal cortex; HC = healthy control; HIV = human immunodeﬁciency virus; HR = high risk;
LR = low risk; MDD = major depressive disorder; mPFC = medial prefrontal cortex; NS = not signiﬁcant; PCC = posterior cingulate cortex; and PD = Parkinson's disease.
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The 5-HT1B receptor is a presynaptic autoreceptor or heteroreceptor
which inhibits serotonin and other monoamine neurotransmitter re-
lease (Svenningsson et al., 2006). Murrough et al. (2011) recently
reported a 20% decrease in 5-HT1B receptor BPND in the ventral striatum
and ventral pallidum of treatment-naïve patients with MDD.Serotonin transporter
The serotonin transporter (5-HTT) literature is summarized in
Table 4. Since the [11C](+)McN5652 radioligand shows non-speciﬁc
binding (Buck et al., 2000), we focus here on the results of studies
using the [11C]DASB radioligand which has a greater ratio of speciﬁc
to non-speciﬁc binding, and therefore allows for the measurement
of BP in cortical as well as subcortical brain regions (Meyer, 2007).
Our group previously reported increased 5-HTT BPND in unmedicated
MDD patients in the thalamus, periaqueductal gray matter (PAG), insula,
and striatum (Cannon et al., 2007). The [11C]DASB binding was signiﬁ-
cantly correlatedwith the severity of depression and anxiety. In currently
depressed patients with BD, we also found increased 5-HTT BPND in
the thalamus, dorsal ACC, medial PFC, and insula as well as decreased
5-HTT BPND in the raphe (Cannon et al., 2006b). In currently remitted
subjects withMDD, in contrast, Bhagwagar et al. (2007) failed to identify
signiﬁcant abnormalities in 5-HTT binding in regions including the amyg-
dala, ACC, hippocampus, and thalamus. Although no difference in 5-HTT
binding was detected by Meyer et al. (2004) in MDD patients versus
healthy controls, scores on the Dysfunctional Attitude Scale were corre-
lated positively with the 5-HTT binding in the PFC, ACC, putamen and
thalamus.
Another group reported decreases in 5-HTT BPND and BPP in MDD.
Reimold et al. (2008) reported reduced thalamic BPND as well as a
negative correlation between 5-HTT availability in the thalamus and
amygdala, and depression and anxiety ratings. More recently they
reported a decrease in BPND in a combined group of OCD and MDD
subjects versus controls (but not MDD patients versus controls) in
the thalamus. The decrease in BPND was associated with higher levels
of cortisol after administration of DEX/CRF in the combined patient
group (Reimold et al., 2011).Dopamine 1 receptor
The literature search yielded three PET studies of the D1 receptor
(Table 6). All three studies used a simpliﬁed reference tissue model to
analyze the data, and reported decreases in D1 BPND in depressed
samples. Using [11C]SCH 23390, Suhara et al. (1992) found a decrease
in BPND in the frontal cortex (but not the striatum) in BD patients who
were only unmedicated for 2 or more days prior to the scan. However,
[11C]SCH 23390 displays relatively poor speciﬁcity which compro-
mises the reliability of the D1 receptor measurement in extrastriatal
areas such as the frontal cortexwhere the density of these receptors is sig-
niﬁcantly lower than in the striatum. Dougherty et al. (2006) reported a
13% reduction in [11C]SCH 23390 binding in the striatum ofMDDpatients
with anger attacks. The authors interpret their data as indicative of a
downregulation of D1 receptors in response to elevated dopamine con-
centrations associated with anger and aggression. Potentially consistent
with this result, we found the mean D1 receptor binding, measured
with [11C]NNC-112, to be 14% lower in the left middle caudate of MDD
subjects compared with healthy controls (Cannon et al., 2009). No signif-
icant difference was found in other striatal regions, the amygdala, insula,
or ACC. However, because the density of the D1 and 5-HT2A receptors are
comparable in the insula and ACC, these results may be confounded by
the fact that [11C]NNC-112 is only 2–3 fold more selective for the D1 re-
ceptor than the 5-HT2A receptor.Dopamine 2 receptor
In two early studies which made use of the D2 receptor family
radioligand, [11C]NMSP, increased Bmax was reported in the caudate
of unmedicated BD patients with psychosis (Pearlson et al., 1995;
Wong et al., 1997). More recent studies have used D2/D3 receptor
radioligands such as [11C]raclopride or [11C]FLB-457. No differences
in extrastriatal D2/3 binding were found using [11C]FLB-457 in medi-
cated patients with MDD (Montgomery et al., 2007; Saijo et al., 2010).
However, Saijo et al. (2010) reported that D2/3 receptor binding de-
creased in the ACC of depressed patients after electroconvulsive thera-
py. No difference in [11C]raclopride binding between manic patients
with BD and healthy controls was found by Yatham et al. (2002). Simi-
larly, Hirvonen et al. (2008b) found no signiﬁcant differences in BPND
between antidepressant-naïve MDD patients and controls, although
they did report a non-signiﬁcant 4% reduction in BPND in the ventral
striatum in MDD. On the other hand, a group of unmedicated MDD pa-
tients with motor retardation displayed increased BPND in the caudate
and striatum compared with healthy controls (Meyer et al., 2006b), al-
though this ﬁnding was not conﬁrmed by the results obtained in a
smaller, medicated sample (Montgomery et al., 2007).
Dopamine transporter
Two studies examined dopamine transporter (DAT) function in
the context of PET imaging (Table 5). Meyer et al. (2001b) found a
14% reduction in BPND in the striatum of unmedicated patients with
MDD, and Anand et al. (2011) reported decreased BPND in the cau-
date, but not the putamen of BD patients relative to healthy controls.
Monoamine oxidase-A
Studies of MAO-A in depression are summarized in Table 6. MAO-
A metabolizes serotonin, norepinephrine, and dopamine. In patients
with MDD, Meyer et al. (2006a) reported an increase in VS averaging
34% in widespread brain regions including the PFC, ACC, caudate, pu-
tamen, and hippocampus. Interestingly, this ﬁnding was replicated in
an independent group of depressed MDD subjects who also showed
greater MAO-A VT compared with controls after SSRI treatment
(Meyer et al., 2009). Moreover, remitted patients who later had a re-
currence of major depression had higher MAO-A VT in the PFC and
ACC than those patients who did not relapse.
Muscarinic 2 receptor
Cannon et al. (2006a) found that M2 receptor binding was de-
creased in the ACC of patients with BD compared with patients with
MDD and healthy controls. Although this is the only published
study of the M2 receptor in BD, as we point out below, this is an im-
portant ﬁnding to pursue because of its relationship with variation in
the M2 receptor gene (CHRM2).
Discussion
Serotonin 1A
While the weight of evidence is suggestive of decreased postsynap-
tic 5-HT1A receptor binding in mood disorders, other researchers, nota-
bly the Columbia group have hypothesized that both presynaptic and
postsynaptic 5-HT1A receptor binding is in fact elevated in mood disor-
ders and have replicated their ﬁnding in independent samples
(reviewed in Shrestha et al., 2012). These authors argue that reports
of decreased BPND are biased by use of the cerebellar gray matter as a
reference region, and reported that when cerebellar white matter was
used as the reference region, BPND was signiﬁcantly higher in remitted
MDD subjects relative to controls (Miller et al., 2009a). In contrast,
Table 5
Dopamine receptor imaging studies in mood disorders.
Study Sample Age Medication/nicotine Receptor Radioligand Method Result
Suhara et al.
(1992)
10 BD 30–63 Unmedicated
2+days
D1 [11C]SCH 23,390 Reference tissue
model (cerebellum)
↓ BPND in frontal
cortex but
not striatum21 HC 20–72 Not reported
Dougherty et al.
(2006)
10 MDD with anger attacks 43.1±7.3 Unmedicated
3+weeks
D1 [11C]SCH 23,390 Compartmental
modeling (cerebellum)
↓ BPND in striatum
10 HC 41.6±6.4 Not reported
Cannon et al.
(2009)
18 MDD 31±11 Unmedicated
3+weeks
D1 [11C]NNC-112 Simpliﬁed reference tissue
model (cerebellum)
↓ BPND in left
middle caudate
19 HC 31±8.5 Smokers excluded
Pearlson et al.
(1995)
7 BD (psychotic) 40±14 Unmedicated
6+months
D2/4 [11C]NMSP Blocked versus non-blocked
calculation of receptor
density (Bmax)
↑ Bmax in caudate
in psychotic BD
7 BD (non-psychotic) 41±13 Not stated
14 HC 28±13
Yatham et al.
(2002)
13 BD (manic) 33±12 Naïve D2/3 [11C]Raclopride Ratio method (cerebellum) NS
14 HC 31±11 Not stated
Meyer et al.
(2006b)
21 MDD 35±10 Unmedicated
26+weeks
D2/3 [11C]Raclopride Simpliﬁed reference tissue
model (cerebellum)
↑ BPND in caudate
and striatum
21 HC 34±11 Smokers excluded
Montgomery et al.
(2007)
7 MDD 44.1±8.7 Medicated D2/3 [11C]FLB-457 Distribution volume
by compartmental
model with plasma
input function
NS
7 HC 35.7±10.9 Mixed smokers and
non-smokers
Montgomery et al.
(2007)
8 MDD 42.6±8.9 Medicated D2/3 [11C]Raclopride Simpliﬁed reference tissue
model (cerebellum)
↓ BPND in medicated
patients in
dorsal but not
ventral striatum
8 HC 38.6±10.3 2 smokers, 14
non-smokers
Hirvonen et al.
(2008b)
25 MDD 40.2±9.0 Naïve D2/3 [11C]Raclopride Simpliﬁed reference tissue
model (cerebellum)
NS
19 HC 39.4±10.5 5 MDD smokers
Meyer et al.
(2001b)
9 MDD 35±8 Unmedicated
3+months
DAT [11C]RTI-32 Simpliﬁed reference tissue
model (cerebellum)
↓ BPND in striatum
23 HC 37±10 Smokers excluded
Anand et al.
(2011)
11 BD 27.3±9.7 Unmedicated
2+weeks
DAT [11C]CFT Simpliﬁed reference tissue
model (cerebellum)
↓ BPND in caudate
but not ventral
striatum13 HC 27.5±7.3 Smokers included
but smoking status not
associated with BPND
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of 5-HT1A receptors) was used as a reference region, the BPND was sig-
niﬁcantly lower in the patient group, suggesting that group differences
in cerebellar gray matter binding exist. Nevertheless, the region-of-
interest deﬁned in the cerebellar gray matter in this study was posi-
tioned too closely to the gray matter of the occipital and temporal cor-
tices, and thus was confounded by the spilling in of radioactivity from
the latter structures (Links et al., 1996; Mazziotta et al., 1981). More-
over, some of the studies that reported reductions in binding in depres-
sion indeed deﬁned their reference ROI in the cerebellar white matter
(e.g., Meltzer et al., 2004), and more recently reported studies that de-
ﬁned the cerebellar ROI in the white matter found reductions in both
BPND and BPF in depressed samples with MDD (Carlson et al., 2008)
and BD (Nugent et al. in press).
Secondly, tracer kinetic modeling is based on the assumption that
the ratio of k1/k2 is identical in the target and reference regions. How-
ever, this assumption is questionable when cerebellar white matter isTable 6
MAO-A imaging studies in mood disorders.
Study Sample Age Medication Status Radi
Meyer et al.
(2006a)
17 MDD 34±8 Unmedicated 5+months [11C
17 HC 34±8
Meyer et al.
(2009)
16 MDD 32±8 Unmedicated 7+months [11C
18 rMDD 31±8
28 HC 32±8
Bacher et al.
(2011)
24 HC smokers
withdrawn from nicotine
36±7 Unmedicated [11Cused as a reference region because cerebral blood ﬂow (k1) is signif-
icantly higher in gray matter than in white matter, and k2 is difﬁcult
to measure accurately.
Thirdly, the calculation of BPND assumes no between group differ-
ences in the free fraction of ligand in the nondisplaceable compartment,
fND. Yet, Sullivan et al. (2009) report a signiﬁcant between-group differ-
ence in fP – the fraction of ligand that is bound to plasma proteins – thus
implying a between group difference in fND. A difference in fP has not
been found in more recent studies of depressed subjects studied using
either 5-HT1A radioligands or radioligands for other receptors.
It has also been argued that BPF is the “gold standard” measure of
receptor binding and therefore results obtained using BPND as an out-
come measure are inaccurate (Parsey et al., 2010; Shrestha et al.,
2012). However, two independent groups have reported reductions
in cortical, hippocampal, and raphe 5-HT1A receptor binding using ar-
terial sampling and full tracer kinetic modeling (Hirvonen et al.,
2008a; Meltzer et al., 2004; Moses-Kolko et al., 2008). We furtheroligand Method Result
]Harmine Logan method with a plasma
arterial input
↑ VS in PFC, temporal cortex,
ACC, PCC,
thalamus, caudate, putamen,
hippocampus, midbrain
]Harmine Logan method with a plasma
arterial input
↑ VT in both MDD and rMDD patients
in multiple brain regions.
↑ VT persisted after SSRI treatment
]Harmine Logan method with a plasma
arterial input
Depressive symptoms associated with
abstinence correlated positively with
VT in PFC and ACC
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BPF or BPP is calculated instead of BPND. We found reductions in BPP in
the ACC, anterior insula, and medial temporal cortex (but not the
raphe) in depressed patients with BD (Carlson et al., 2008; Nugent
et al. in press). Furthermore, we found no group difference in fP.
Theoretically, the discrepancies in the direction of abnormalities
of 5-HT1A binding in depressed subjects versus controls in the Columbia
series relative to those from other laboratories may reﬂect biological
heterogeneity across the depressed samples, as opposed to technical
differences in themeasurement of receptor speciﬁc radiotracer binding.
This possibility appears compatible with the discrepancies in the 5-HTT
binding inMDD reported across these laboratories, despite their having
applied similarmethods formeasuring 5-HTT BPND. For example,we re-
cently found that BPP was inversely correlated with trough plasma cor-
tisol levels in the mesiotemporal cortex (Nugent et al. in press).
However, not all patients with MDD display hypothalamic–pituitary–
adrenal (HPA) axis abnormalities. The Drevets series participants suf-
fered from familial, primary, recurrent mood disorders and as a group
showed abnormally elevated stress plasma cortisol concentrations
(Drevets et al., 1999, 2007), while other studies have included patients
with depression secondary to other medical conditions. Moreover,
glucocorticoids have been shown to exert opposing effects on central
serotonergic transmission depending on their concentration. Levels
of glucocorticoids at the lower end of the normal diurnal range
(corresponding to the trough) stimulated serotonergic neurotrans-
mission whereas glucocorticoid concentrations at the mid-point of
the normal diurnal range suppressed serotonergic neurotransmission
(Judge et al., 2004). Nevertheless, overwhelming evidence indicated
that elevated concentrations of glucocorticoid hormones, particularly
within the context of repeated stress, lead to a reduction in 5-HT1A re-
ceptor expression (reviewed in Savitz et al., 2009).
The hypothesis that 5-HT1A receptor function is reduced in mood
disorders receives support from a recent PET study of previously
healthy subjects exposed to a severe recent stressor. Compared with
non-stressed subjects, stressed subjects displayed reduced BPND in
the ACC, insula and hippocampus, with a trend toward signiﬁcance
in the amygdala, DLPFC, parietal cortex, temporal cortex, and raphe
(Jovanovic et al., 2011). In addition, non-human primate studies pro-
vide support to the PET studies that have reported a reduction in
5-HT1A BPND. Reduced 5-HT1A receptor distribution volume/BPP was
found in the raphe nuclei, amygdala, hippocampus, and ACC in a
PET study of subordinate cynomolgusmonkeyswho showed behavioral
signs of depression after exposure to social defeat (Shively et al., 2006).
In another study, parentally-deprived monkeys were found to have re-
duced hippocampal WAY-100635 binding, and mRNA expression rela-
tive to their normally-reared siblings (although 5-HT1A receptor
binding was actually increased in the dentate gyrus and CA3 ﬁeld in
males) (Law et al., 2008).
Reports of decreased 5-HT1A receptor binding in mood disorders
are also potentially consistent with a combined PET and fMRI study
of 20 healthy individuals that examined the correlation between
5-HT1A receptor binding measured using [11C]WAY100635 and
threat-related amygdala activity measured using an fMRI task (Fisher
et al., 2006). A reduction in 5-HT1A BP in the raphe was associated
with increased BOLD amygdala response to threatening faces (Fisher
et al., 2006), a replicated biomarker of MDD (Savitz and Drevets,
2009). Moreover, decreasing amygdala 5-HT1A BP was associated with
increasing amygdala reactivity to threatening faces (Fisher et al., 2006).
Genetic studies provide additional support to the hypothesis that
post-synaptic 5-HT1A receptor function is reduced in depression.
The G allele of the rs6295 HTR1A polymorphism, which has been pos-
tulated to decrease expression of the postsynaptic 5-HT1A receptor,
(but increase the expression of the 5-HT1A autoreceptor), was found
to be over-represented in MDD and is associated with suicidality
(Albert and Francois, 2010; Lemonde et al., 2003). In addition, the
short, putative risk allele for depression of the serotonin transportergene promoter polymorphism (5-HTTLPR) was associated with re-
duced 5-HT1A receptor binding in 18 different regions of interest, in-
cluding the raphe, hippocampus, amygdala, and PFC (David et al.,
2005). In an epigenetic study, increased methylation of the promoter
region of the 5-HT1A receptor gene, indicative of decreased 5-HT1A re-
ceptor expression, was found in the PFC region of subjects who had
committed suicide (Albert et al., 2008).
As reviewed in Savitz et al. (2009), the postmortem MDD litera-
ture is largely indicative of reduced 5-HT1A receptor mRNA, binding
and/or numbers in the ventrolateral prefrontal cortex and the tempo-
ral polar cortex (Bowen et al., 1989), caudal aspects of the dorsal
raphe (Arango et al., 2001; Boldrini et al., 2008), dorsolateral prefron-
tal cortex (DLPFC) and hippocampus (Lopez-Figueroa et al., 2004),
BA10 of the prefrontal cortex (PFC) in females (Szewczyk et al.,
2008), hippocampus (Lopez et al., 1998), and orbitofrontal cortex
(OFC) (Anisman et al., 2008).
Nevertheless, other reports of increased 5-HT1A receptor density
and/or binding in mood disorders suggest that the direction of abnor-
mality with respect to healthy controls may differ on the basis of co-
morbid conditions, concurrent medications or anatomical region.
Arango et al. (1995) reported that the binding of a 5-HT1A receptor
agonist was increased in MDD in the ventrolateral PFC. However, they
later found that the elevation was attributable to depressed cases with
co-morbid alcoholism. Non-alcoholic depressed cases showed nodiffer-
ence compared to controls in agonist binding (V. Arango, personal com-
munication). Gray et al. (2006) reported increased [3H]8-OH-DPAT
binding in the cortex (BA 9, 10, 40 and 46) of a sample of BD I subjects,
half of whom were treated with lithium before death. Notably a pro-
spective study of the effect of mood stabilizer treatment in BD showed
that lithium and divalproex treatment increased the post-synaptic
5-HT1A receptor binding in several regions, reversing the baseline
reduction in binding evident in the same subjects (Nugent et al. in
press). Other groups have reported increased 5-HT1A receptor density
in the dorsal raphe but these ﬁndings appear speciﬁc to rostral, ventro-
lateral and dorsal subnuclei (Boldrini et al., 2008; Stockmeier et al.,
1998). In contrast, Boldrini et al. (2008) reported lower 5-HT1A receptor
binding in the caudal sub-nucleus of the raphe.
Preclinical studies are also indicative of a decrease in postsynaptic
5-HT1A receptor function although the functional status of the 5-HT1A
autoreceptor is more equivocal. Inactivation of 5-HT1A postsynaptic
receptors in the frontal cortex during development, but not in adult-
hood, produces analogs of anxiety in adult mice (Gross et al., 2002).
Consistent with this study, mice genetically-engineered to over-
express the 5-HT1A receptor in the cortex and hippocampus show
an antidepressant-like effect when subjected to the forced-swim
test, a rodent model of depression (Gunther et al., 2011). Similarly,
mice engineered to under-express the post-synaptic 5-HT1A receptor
show increased depression-related behavior (Richardson-Jones et al.,
2009). Using autoradiography and radioimmunoassays in a rodent
model of epilepsy-associated depression, Pineda et al. (2011) reported
an increase in corticosterone levels concomitant with an increase in
5-HT1A autoreceptor activity and a reduction in hippocampal 5-HT1A
receptor function. Pharmacological activation of the hippocampal
5-HT1A receptor ameliorated the depressive behavior.
The mechanism of action of antidepressant medications provides
further evidence that depression is associated with decreased sero-
tonergic signaling at the postsynaptic 5-HT1A receptor. Tricyclic an-
tidepressants putatively enhance the sensitivity of the post-synaptic
5-HT1A receptor and thus tonic serotonergic transmission via their
effect on the 5-HT1A receptor-associated G proteins (Blier and
Bouchard, 1994; Rossi et al., 2006). Moreover, the increased sensi-
tivity of post-synaptic 5-HT1A receptors also occurs in limbic struc-
tures following administration of electroconvulsive shock (ECS)
(Ishihara and Sasa, 1999) and the selective norepinephrine reuptake
inhibitor, reboxetine (Szabo and Blier, 2001). On the other hand,
some data suggest that the 5-HT1A autoreceptor may be upregulated
57J.B. Savitz, W.C. Drevets / Neurobiology of Disease 52 (2013) 49–65or sensitized in depression. For example, SSRIs are hypothesized to
enhance serotonergic neurotransmission by desensitizing 5-HT1A
autoreceptors in the raphe thereby increasing postsynaptic 5-HT1A
receptor signaling (Blier et al., 1987, 1998).
Interim summary
The 5-HT1A literature is in disagreement over whether serotoner-
gic signaling at 5-HT1A receptors is increased or decreased in mood
disorders. Based on the imaging, postmortem, genetic, and preclinical
literature discussed above the predominant weight of evidence favors
the hypothesis that postsynaptic 5-HT1A receptor binding or density in
themesiotemporal cortex is reduced indepression— although thisﬁnd-
ing may be speciﬁc to individuals who show elevations in circulating
cortisol levels.We also hypothesize that the discrepancy in the direction
of 5-HT1A autoreceptor bindingmay be related to functional differences
in subregions of raphe that cannot be detected with the current resolu-
tion of PET. As mentioned above, postmortem studies have suggested
that 5-HT1A receptor binding is increased in the rostral, ventrolateral
and dorsal subnuclei of the raphe but decreased in the caudal sub-
nucleus of the raphe (Boldrini et al., 2008; Stockmeier et al., 1998).
A simpliﬁed model of 5-HT1A receptor dysfunction in mood disorders
The 5-HT1A receptor is concentrated in the raphe in the form of an
autoreceptor that exerts inhibitory effects on serotonin synthesis and
release, as well as in the corticolimbic region in the form of either re-
ceptors that inhibit pyramidal cell ﬁring activity or heteroreceptors.
Theoretically, chronic stress-related serotonin release may down-
regulate or desensitize postsynaptic 5-HT1A receptors, explaining
the reduction in 5-HT1A receptor numbers or binding often reported
at postmortem and in PET imaging studies. The reduction in 5-HT1A
receptor function may result in part from stress-induced secretion
of corticosteroids which in animal models downregulate the genetic
expression of postsynaptic 5-HT1A receptors (reviewed in Savitz et
al., 2009). Antidepressant medications putatively enhance serotoner-
gic signaling at the postsynaptic receptor either by desensitizing the
somatodendritic autoreceptor or by facilitating the activation of G
proteins associated with the postsynaptic 5-HT1A receptor.
Serotonin 2A
A review of Table 3 raises the possibility that reports of decreased
5-HT2A receptor binding in mood disorders may have been confound-
ed by the effects of antidepressant treatment which has been shown
to downregulate the 5-HT2A receptor (Meyer et al., 2001a). In three
studies reporting decreased 5-HT2A receptor binding, patients were
unmedicated for 1–4 weeks prior to imaging while Bhagwagar et al.
(2006) reported increased cortical BPP in patients who were
unmedicated for at least 6 months prior to imaging. Other con-
founding factors may be comorbid alcohol abuse and obesity, which
are more prevalent in mood disorders than in the general population.
A family history of alcohol abuse has been associated with reduced
5-HT2A receptor binding in the PFC at postmortem (Underwood et al.,
2008) while cortical 5-HT2A receptor binding was positively associated
with bodymass index (BMI) in an [18F]altanserin PET study (Erritzoe et
al., 2009).
Given the lack of clarity in PET studies of the 5-HT2A receptor in
mood disorders, it may also be instructive to examine mood
disorder-related subphenotypes. At least four studies have examined
the association between mood disorder-associated personality traits
and 5-HT2A receptor binding potential in healthy individuals. “Neu-
roticism”, a personality trait associated with increased risk for depres-
sion, also was associated with increased BPP in the entorhinal cortex,
superior and inferior frontal cortices, and posterior cingulate cortex
(Frokjaer et al., 2008), and in a follow-up study, individuals with afamily-history of MDD or BD showed a positive association between
“neuroticism” and 5-HT2A receptor binding in the OFC, ACC, entorhi-
nal cortex, and hippocampus (Frokjaer et al., 2010). Similarly, hippo-
campal BPP measured with [18F]altanserin was found to be positively
correlated with the personality trait, “negativism” in females (Soloff
et al., 2010). In contrast, an inverse relationship between [18F]FESP
binding and “harm avoidance” was found in regions such as the infe-
rior frontal gyrus, middle and inferior temporal gyrus, ACC, and hypo-
thalamus (Moresco et al., 2002).
In contrast to the results of most PET studies, the postmortem litera-
ture is generally indicative of increased 5-HT2A receptor density inmood
disorders although many negative ﬁndings have been published
(reviewed in Stockmeier, 2003). Increased 5-HT2A receptor levels have
been reported in BA8/9 (Stanley and Mann, 1983; Turecki et al.,
1999), BA9 (Arango et al., 1990), BA9 and amygdala (Hrdina et al.,
1993), BA9/10/11 (Arranz et al., 1994), BA8/9 and hippocampus
(Pandey et al., 2002), frontopolar cortex and amygdala (Anisman et
al., 2008) and BA10 (Shelton et al., 2009).
Potentially consistent with the reports of increased 5-HT2A recep-
tor function in mood disorders at postmortem, preclinical studies
demonstrate that antidepressant medication reduces the density of
5-HT2A receptors in rodents (Carr and Lucki, 2011). Similarly, activa-
tion of 5-HT2A receptor in the limbic forebrain increases anxious be-
havior while blocking the 5-HT2A receptor reduces anxiety, perhaps
explainingwhy theHTR2A knock-out produces a low-anxiety behavior-
al phenotype in mice (Weisstaub et al., 2006).
Interim summary
Although there are ﬁve extant reports of decreased 5-HT2A recep-
tor binding in mood disordered samples assessed using PET imaging,
the personality, postmortem, and preclinical literature suggest that
the 5-HT2A receptor may be upregulated in certain populations of pa-
tients with mood disorders.
A simpliﬁed model of 5-HT2A receptor dysfunction in mood disorders
The 5-HT2A receptor is predominantly located on cortical gluta-
matergic pyramidal neurons and γ-aminobutyric acid (GABA) interneu-
rons (Santana et al., 2004). At least in rodents, chronic corticosterone
administration increases cortical 5-HT2A receptor expression and in-
duces the development of behavioral analogs of depression (Fernandes
et al., 1997; Kuroda et al., 1992). Similarly, in mice over-expressing the
glucocorticoid receptor (GR), 5-HT2A receptor levels and 5-HT2A recep-
tor binding was increased in the hippocampus (Trajkovska et al., 2009).
More recently, Magalhaes et al. (2010) reported that administration of
CRF into the prefrontal cortex of mice induced behavioral analogs of
anxiety in conjunction with increased cell surface expression and sig-
naling at the 5-HT2 receptor. The 5-HT2A receptor is also found in the
paraventricular nucleus of the hypothalamus,where it exerts an excitato-
ry effect, facilitating the secretion of cortisol releasing factor (CRF) during
stress (Zhang et al., 2002).While short-term glucocorticoid activity also
increases 5-HT2A receptor expression in the hypothalamus, prolonged
elevations in circulating glucocorticoids may desensitize the 5-HT2A re-
ceptor, preventing further activation of the HPA axis (Lee et al., 2009).
Conceivably, elevations in circulating levels of cortisol may explain
the increased 5-HT2A receptor BP observed in some PET studies. The
fact that not all depressed patients show glucocorticoid resistance
may partly explain the divergent ﬁndings in the literature. Theoreti-
cally, antidepressant medications that increase serotonergic signaling
at the 5-HT1A receptor or antagonize the 5-HT2A receptor may over-
come the serotonin signaling abnormality and downregulate or de-
sensitize corticolimbic 5-HT2A receptors. Potentially consistent with
this hypothesis, chronic administration of selective serotonin reup-
take inhibitors (SSRI) has been shown to decrease 5-HT2A receptor
1 A SNP in the long 5-HTTLPR variant results in two additional alleles, LA and LG. LG
is functionally similar to the short 5-HTTLPR allele.
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Syvalahti et al., 2006; Yamauchi et al., 2006).
Serotonin 1B
Supporting evidence for the reduction in 5-HT1B function in MDD
emanates from both preclinical and postmortem data. Svenningsson et
al. (2006) focused on p11, a protein which potentiates 5-HT1B function
by impacting the intracellular trafﬁcking and cell surface expression of
5-HT1B. The authors found that antidepressant medication increased
the level of p11 in the forebrain while mice that overexpressed p11
showed similar behavioral characteristics to the antidepressant-
treated mice. Consistent with these data, p11 knockout mice showed
behavioral analogs of depression including a decreased responsiveness
to sucrose. Moreover, Svenningsson et al. (2006) reported both reduced
mRNA and protein expression of p11 in the ACC of people who had suf-
fered from MDD. Consistent with these data, Anisman et al. (2008)
reported a reduction in 5-HT1BmRNA expression in the frontopolar cor-
tex, OFC and hippocampus of patients who had committed suicide. P11
expressionwas also decreased in the amygdala, hippocampus, OFC, and
frontopolar cortex (Anisman et al., 2008).
Serotonin transporter
Evidence for 5-HTT binding in mood disorders has been mixed
with both increases, decreases and negative ﬁndings reported
(reviewed in Savitz and Drevets, 2009). In addition to the type of
radioligand, a number of potential confounds may contribute the dis-
crepancy in results across studies. For instance, Praschak-Rieder et al.
(2008) observed that 5-HTT BP correlated negatively with daily hours
of sunshine with higher BP in the fall and winter months compared
with spring and summer. BMI is another potential confound as the
5-HTT BPND is negatively correlated with BMI in the caudate, putamen
and thalamus (Erritzoe et al., 2010).
PET imaging studies of depression-related phenotypes generally
support the hypothesis that 5-HTT binding is increased in patients
with mood disorders. Neuroticism was found to be associated with
higher thalamic BP in humans (Takano et al., 2007) while 5-HTT avail-
ability in the amygdala was positively associated with anxious temper-
ament in rhesus monkeys (Oler et al., 2009). In addition, Boileau et al.
(2008) detected increased 5-HTT BPND in the dorsolateral PFC in clini-
cally depressed patients with Parkinson's disease (PD), and another
study similarly reported increased 5-HTTBPP in several regions, including
the amygdala, hypothalamus, raphe, and posterior cingulate cortex in de-
pressed versus non-depressed PD patients (Politis et al., 2010). HIV posi-
tive patientswith depression also showed increased BPND in regions such
as the midbrain, thalamus, putamen, caudate, and ACC compared with
HIV positive patients without depression (Hammoud et al., 2010). Par-
ticipants in these PD and HIV studies were unmedicated and in some
cases antidepressant medication-naive.
Rats that display various behavioral analogs of depression show
increased hippocampal serotonin levels (Keck et al., 2005) as well
as elevated 5-HTT density and serotonin concentrations (Grecksch
et al., 1997). Since CRF has been shown to increase serotonin release
in rodents, one possible explanation for the increase in 5-HTT binding
is a stress-induced compensatory upregulation of 5-HTT expression in
response to the elevation in serotonergic transmission. Alternatively,
an increase in 5-HTT binding may result from increased 5-HTT trafﬁck-
ing from the cytosol to the membrane (Blakely et al., 1998). Radio-
tracers tend to show greater afﬁnity for receptors situated on the cell
membrane comparedwith the cytosol (Laruelle et al., 1988)— although
this divergence in afﬁnity has not been characterized for DASB.
The postulated increase in 5-HTT activity receives additional sup-
port from the psychoneuroimmunology literature. Zhu et al. (2010)
showed that intraperitoneal injection of lipopolysaccharide (LPS) in-
duced behavioral despair by enhancing brain 5-HTT activity throughIL-1R and p38 MAPK pathways. A previous in vitro study showed
that IL1-B administration increases the afﬁnity of the 5-HTT for sero-
tonin (Zhu et al., 2006).
On the other hand, there is contradictory evidence suggesting that
5-HTT function is reduced in mood disorders. Frokjaer et al. (2009)
found that healthy individuals who were at high risk of developing
MDD by virtue of having a co-twin with the disorder, displayed re-
duced 5-HTT BPND in the DLPFC and the ACC compared with low-
risk individuals. Nevertheless, in the absence of a longitudinal study,
one cannot be sure which “high-risk” individuals are truly vulnerable
to developing depression, and which individuals are resilient.
Consistent with the PET imaging studies that have reported a
mood disorder-associated reduction in 5-HTT BP, a review of the
postmortem literature concluded that studies using selective 5-HTT
ligands report either reductions or no changes in 5-HTT levels in the
cerebral cortex (Stockmeier, 2003). More recent studies support this
conclusion. While no change in 5-HTT mRNA expression was reported
in the dorsal raphe (Anisman et al., 2008), a decrease in the density of
serotonin-synthesizing neurons, often together with a reduction in
5-HTT binding, was found in the dorsal and ventral PFCs (Underwood
et al., 2011), and the dorsal raphe (Arango et al., 2001; Baumann et al.,
2002).
Lower 5-HTT BP might reﬂect a downregulation of 5-HTT in re-
sponse to lower intrasynaptic levels of serotonin, a loss of raphe sero-
tonergic projections to corticolimbic regions, or a decrease in SLC6A4
gene expression (Frokjaer et al., 2009). The reduction in the cere-
brospinal ﬂuid (CSF) concentration of the serotonin metabolite,
5-hydroxyindoleacetic acid (5-HIAA), that is found in mood disorder
patients with a history of suicidal behavior (Asberg, 1997; Mann and
Currier, 2007) could be interpreted as being consistent with a decrease
in serotonergic transmission. However, not all studies of mood disorder
patients ﬁnd reductions in 5-HIAA — see for example Barton et al.
(2008). The effect appears to be more strongly related to impulsivity
and violence than depression, per se. In addition, a reduction in
serotonin turnover could also be interpreted as reﬂecting greater
5-HTT-mediated reuptake and vesicular packaging of intrasynaptic se-
rotonin which decreases the breakdown of serotonin by monoamine
oxidase A. Consistent with this possibility, Heinz et al. (1998) found
that reduced concentrations of 5-HIAA were associated with increased
brainstem 5-HTT BP.
At ﬁrst glance, the fact that the short, low-activity allele of the pro-
moter polymorphism of the 5-HTT gene (5-HTTLPR) putatively pre-
disposes to depression in the context of stress (Caspi et al., 2003;
Karg et al., 2011), appears to be congruent with reports of reduced
5-HTT BP in mood disorders.
Nevertheless, the in vivo effect of the 5-HTTLPR variant on 5-HTT
expression is somewhat controversial. While three studies reported
that subjects homozygous for the long allele displayed increased
5-HTT binding in the putamen (Praschak-Rieder et al., 2007), mid-
brain (Reimold et al., 2007), and caudate (Kalbitzer et al., 2010), in
contrast, (Parsey et al., 2006a) and (Murthy et al., 2010) found no ef-
fect of the 5-HTTLPR variant on [11C]McN5652 and [11C]DASB bind-
ing, respectively. Similarly, [11C]DASB binding was not signiﬁcantly
affected by 5-HTTLPR genotype in rhesus monkeys (Christian et al.,
2009). In their review of the literature, Willeit and Praschak-Rieder
(2010) conclude that 5-HTTLPR does have an effect on in vivo
5-HTT binding when subjects are genotyped for the so-called triallelic
polymorphism,1 however, the effect is weakened by factors such as li-
gand quality, psychiatric diagnosis and seasonality.
Even if the short, “risk” allele is associated with reduced 5-HTT
binding, this effect is not necessarily incompatible with increased
5-HTT function in depression. Firstly, although the short allele of the
5-HTTLPR polymorphism appears to predispose to depression in the
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tective in the absence of psychosocial adversity (Homberg and
Lesch, 2011; Van den Hove et al., 2011). Secondly, the impact of the
5-HTTLPR polymorphism on 5-HTT function may be more signiﬁcant
prenatally or during childhood (Sibille and Lewis, 2006) where con-
ceivably an abnormal increase in serotonergic signaling can exert det-
rimental effects on cell migration, neurogenesis and apoptosis.
Interim summary
The PET 5-HTT data in mood disorders are mixed. Nevertheless,
based on imaging studies of depression-related phenotypes, the pre-
clinical, and the neuroimmunology literatures, we hypothesize that
5-HTT function is increased in depression.
A simpliﬁed hypothesis of serotonin transporter dysfunction in mood
disorders
Increased serotonergic transmission in response to depression-
related elevations in CRF and/or inﬂammation conceivably results in
an increase in 5-HTT function leading to chronic overactivity of the
5-HTT and decreased serotonergic neurotransmission. Future re-
search in preclinical models of depression may elucidate whether ele-
vated 5-HTT activity is an acute response to the increase in serotonergic
neurotransmission associated with a stressor or whether exposure to
a stressor can result in a chronic upregulation of the 5-HTT.
The D1 receptor
PET assessments of D1 receptor binding have emphasized the stri-
atum due to the relatively low speciﬁc-to-nonspeciﬁc binding in
extra-striatal tissues. The extant PET data are suggestive of a decrease
in D1 receptor availability in the striatum. Postmortem studies, in
contrast, have focused on extrastriatal regions. The percentage of
D1-expressing neurons together with D1 mRNA expression was
reported to be increased by 25% in the CA3 region of the hippocampus
(Pantazopoulos et al., 2004) in BD subjects versus controls, but to not
differ from controls in the amygdala of MDD subjects (Xiang et al.,
2008).
The hypothesis that the D1 receptor function is decreased in the
striatum of depressed patients receives some support from a rat
model of anhedonia. Anhedonic rats show a decreased dopaminergic
response in the nucleus accumbens (NAc) to palatable food concurrent
with decreased sensitivity of the D1 receptor (Scheggi et al., 2011). Fur-
ther, in rhesusmonkeys, electroconvulsive therapy (ECT) resulted in in-
creased dopaminergic neurotransmission in the striatum together with
transient increases in D1 receptor binding (Landau et al., 2011).
The D2/3 receptor
The preclinical literature suggested the hypothesis that D2/3 re-
ceptor binding would be increased in depression. Rats exposed to
chronic social stress show increased D2, but not D1, receptor binding
in the striatum (Lucas et al., 2004), and both maternal deprivation
and chronic mild stress lead to an increase in D2 mRNA expression
in the striatum (Zhu et al., 2011). Moreover, dopamine receptor ago-
nists exert antidepressant effects in rodent models of depression via
activation of the D2/3 receptor (Basso et al., 2005).
Two postmortem receptor binding studies have found no differ-
ence in basal ganglia D2 receptor binding between suicide victims
and controls (Allard and Norlen, 2001; Bowden et al., 1997). On the
other hand, Klimek et al. (2002) initially reported increased D2 recep-
tor binding in the amygdalae of depressed patients, but were subse-
quently unable to replicate this ﬁnding (Xiang et al., 2008).
Imaging studies of mood disorder-related phenotypes provide
mixed evidence for increased D2/3 receptor function in MDD.Enhanced BOLD response of the amygdala to unpleasant pictures, a
potential biomarker of depression, was found to correlate negatively
with [18F]fallypride BPND in the striatum but positively with [18F]
fallypride BPND in the amygdala, insula, and ACC (Kobiella et al.,
2010). Kestler et al. (2000) reported a positive correlation between
[11C]raclopride binding in the striatum and Depression score on the
NEO PI-R personality inventory. In contrast, a more recent high-
resolution PET study found an inverse relationship between the
depression-related personality trait, “harm avoidance”, and D2/3 dis-
tribution volume in the dorsal caudate and putamen in healthy indi-
viduals (Kim et al., 2011). Notably, the inverse correlation between
harm avoidance and D2/3 receptor availability was found in the dor-
sal association and sensorimotor regions of the striatumwhere D2 re-
ceptor signaling has been associated with psychomotor activity,
rather than the ventral striatum where D2 receptor signaling has
been more closely related to reward and motivation.
One potential confound which is not always addressed in the litera-
ture is smoking status. Nicotine can inﬂuence D2/3 receptor binding in
the ventral striatum. For example, in the Kobiella et al.'s (2010) study
cited above, smokers showed an attenuated amygdala BOLD response
to unpleasant stimuli compared with non-smokers. In the Kim et al.'s
(2011) study, which showed a negative correlation between harm
avoidance andD2/3 distribution volume in the dorsal caudate and puta-
men, 20% of the subjects were smokers. Meyer et al. (2006b), who
reported increased D2/3 BPND in the caudate and striatum in depression
excluded smokers from their study. However, other groups reporting
reducedD2/3 receptor binding or non-signiﬁcant results have generally
included smokers in their studies or have not provided details regarding
smoking status (Table 5).
Interim summary
The functional status of the D2/3 receptor in depression is unclear.
Discrepant ﬁndings in the literature may partly relate to incomplete
control of nicotine use and to the sensitivity of some PET radioligands
to endogenous dopamine concentrations (i.e., [11C]raclopride and
[18F]fallypride). Conceivably the use of such D2/3 receptor ligands in
paradigms that assess dopamine release in response to unpredictable
reward may provide more reproducible results across studies.
The dopamine transporter
The only two PET studies that have examined DAT function in
mood disorders are indicative of a decrease in BPND in the striatum.
Consistent with these data, rhesus monkeys subjected to ECT showed
increases in DAT and vesicular monoamine transporter binding post-
ECT that returned to normal within 6 weeks (Landau et al., 2011).
Striatal DAT levels have not to our knowledge been examined in post-
mortem patients but reduced concentrations of DAT were found in
the central and basal nuclei of the amygdala in postmortem MDD
cases (Klimek et al., 2002).
A simpliﬁed model of dopamine receptor and DAT dysfunction in mood
disorders
Dopamine receptor function varies across different brain regions.
Although the D1 receptor is preferentially localized to GABAergic
neurons in the PFC (Smiley and Goldman-Rakic, 1993), here we
limit our discussion to the striatum since most PET studies have fo-
cused exclusively on this brain region. The PET literature has also
been limited to BP measurement under resting state conditions and
we note that the heuristic model of dopamine receptor function out-
lined below may differ with respect to dopamine release in response
to unpredicted reward or other types of reward learning paradigms.
Preclinical models in rodents have emphasized the shell region of
the NAc, part of the ventral striatum, as playing an important role in
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mates, however, the cells that manifest the histochemical and con-
nectional features of the NAc shell region are distributed throughout
the anteroventral striatum (accumbens area, ventromedial caudate,
anteroventral putamen; reviewed in Drevets et al., 1999). The ventral
striatum receives excitatory glutamatergic projections from the PFC,
the amygdala, and the subiculum, as well as modulatory dopaminer-
gic projections from the ventral tegmental area (VTA) (Sesack and
Grace, 2010). Both the excitatory afferents and the modulatory dopa-
minergic afferents synapse onto the spines of GABAergic medium
spiny neurons which express both D1 and D2 receptors (Surmeier
et al., 2007). D2 receptor signaling inhibits NAc activity, while D1 re-
ceptor signaling enhances NAc function (Sesack and Grace, 2010).
Dopamine neurons switch to phasic burst ﬁring when exposed to
stimuli that signal a reward. Because D1 receptors are in a low-
afﬁnity state compared with D2 receptors, they are primarily activated
byphasic reward-related dopamine-release (Schultz, 2010). In contrast,
low levels of dopamine primarily activate high-afﬁnity D2 receptors
(Schultz, 2010). It could therefore be speculated that the decrease in
D1 receptor BP is associatedwith the deﬁcit inmotivated behavior char-
acteristic of some types of depression. The putative decrease in DAT BP,
may reﬂect the impact of inﬂammation (see below) and/or a compensa-
tory response to decreased dopaminergic signaling in the ventral stria-
tum. In support of this hypothesis, DAT decreases in density after
chronic dopamine depletion (Gordon et al., 1996). In other words, at
least some types of depression may be associated with low basal levels
of intrasynaptic dopamine. Conceivably these individuals may be pre-
disposed to a greater reward-associated dopamine release, and conse-
quently a heightened vulnerability to addiction.
Nevertheless, we note that the biological role played by dopamine
receptors in reward and anhedonia is likely to be complex. For example,
one complicating factor is that D1 and D2 receptors can form a
heteromer in the ventral striatum, which allows dopamine to enhance
the expression of BDNF together with the maturation, differentiation
and growth of neurons (Hasbi et al., 2009). Somewhat counterintuitive-
ly, the D1–D2 heteromerwas found to be upregulated in the striatum of
MDD subjects comparedwith control subjects studied postmortem.No-
tably, disruption of the complex exerted antidepressant effects in rats
undergoing the forced-swim test (Pei et al., 2010). The effect of the
D1–D2 receptor complex on measurements of BP in the context of
PET imaging is currently unknown.
Monoamine oxidase-A
The evidence for increased MAO-A density in depression receives
indirect support from a PET study of healthy smokers who were
acutely withdrawn from nicotine. Withdrawal from nicotine was as-
sociated with an increase in VT in the PFC and ACC, and the depressive
symptoms associated with smoking abstinence were positively corre-
lated with VT (Bacher et al., 2011). The same group also recently
reported that the early post-partum period is associated with an
increase (≈40%) in MAO-A VT in the PFC, ACC, temporal cortex, thala-
mus, putamen, hippocampus, and midbrain, perhaps contributing to
the pathogenesis of post-partum depression (Sacher et al., 2010). In a
somewhat contradictory result, a personality trait derived from the NEO
neuroticism scale (which the authors have labeled as anger–hostility)
was negatively correlated with MAO-A VT in the PFC in healthy indi-
viduals (Soliman et al., 2011).
In an early quantitative autoradiography study of postmortem
samples with MDD, Ordway et al. (1999) failed to detect a signiﬁcant
difference in MAO-A binding in the locus coeruleus and raphe be-
tween MDD subjects and healthy controls. A recent postmortem
study showed that R1, a transcriptional repressor of MAO-A was de-
creased by 30–38% in the PFC ofmedicated and unmedicated individuals
withMDD (Johnson et al., 2011). Further, MAO-A activity was increased
by 40% in the unmedicated MDD sample (Johnson et al., 2011). Thisresult is consistent with a previous report of reduced R1 in the OFC
of violent suicide victims (Thalmeier et al., 2008).
A simpliﬁed hypothesis of MAO-A dysfunction in mood disorders
Meyer et al. (2006a) hypothesize that the elevated density of MAO-
A in depression is the primary driver of the reduction in monoaminer-
gic signaling. The functional status of the individual monoamine trans-
porters (i.e. 5-HTT, DAT, and NET) then exerts a secondary inﬂuence on
speciﬁc extracellular monoamine levels, and together with MAO-A, de-
termine the severity and symptom proﬁles of the depressive episode.
The same group later reported an elevation in MAO-A in remitted de-
pressed patients aswell as an elevation inMAO-A in depressedMDDpa-
tients treated with SSRI medication, suggesting that increased MAO-A
density is a trait marker of MDD (Meyer et al., 2009).
The muscarinic 2 receptor
[18F]FP-TZTP is an agonist and binds to M2 autoreceptors in the
high-afﬁnity state. This property of [18F]FP-TZTP makes its binding
sensitive to endogenous acetylcholine which may desensitize the M2
receptor or compete with [18F]FP-TZTP for the M2 receptor (Cannon
et al., 2006a). Thus the ﬁnding of decreased M2 receptor binding in
BD is supported by observations that administration of the acetylcholin-
esterase inhibitor, physostigmine, can worsen depressive symptoms
(Cannon et al., 2006a). Furthermore, the antimuscarinic drug, sco-
polamine, was shown to exert antidepressant effects in currently de-
pressed patients withMDD or BD (Furey and Drevets, 2006) (Drevets
and Furey, 2010).
The ﬁnding that M2 receptor binding is decreased in patients with
BD also receives support from a genetic study which demonstrated a
disjunction in the effects of a SNP (rs324650) in the M2 gene
(CHRM2) on [18F]FP-TZTP binding in patients with BD versus healthy
controls (Cannon et al., 2011). In the healthy control group, the thymine
(T) allele was associated with greater M2 receptor binding whereas in
the BD group, the T allele was associated with a reduction in M2 recep-
tor binding.
A heuristic model of extant neuroreceptor imaging data
Preclinical data show that IL1β administration increases the afﬁnity
of the 5-HTT for serotonin (Zhu et al., 2006). The same group also
showed that intraperitoneal injection of lipopolysaccharide (LPS) in-
duced behavioral despair by enhancing brain 5-HTT activity through
IL-1R and p38 MAPK pathways (Zhu et al., 2010). Consistent with
these data, the selective serotonin reuptake inhibitors (SSRIs), paroxe-
tine and sertraline, inhibited the generation of nitric oxide (NO) and
tumor necrosis factor (TNF) from activated microglial cells (Horikawa
et al., 2010).
Cytokines such as IFNα also decrease concentrations of CNS dopa-
mine (Capuron and Miller, 2011). Reports are conﬂicting as to whether
this decrease in dopamine is correlated with an upregulation of DAT as
reported byMoron et al. (2003) or a downregulation of DAT as reported
by Lai et al. (2009). LPS-induced cytokine production bymacrophages is
enhanced in DAT-knockoutmice (Kavelaars et al., 2005). Further,Wang
et al. (2009) showed that a single injection of LPS in pregnant rats on
gestation day 10 when dopamine and serotonin neurons ﬁrst emerge,
causes signiﬁcant loss of neurons in the substantia nigra and dorsal
raphe, respectively. In a follow-up study, the offspring of the LPS-
exposed rats showed increased anxiety-like behavior along with a sig-
niﬁcant decrease in dopamine in the NAc and decrease in serotonin in
themedial PFC and ventral hippocampus (Lin et al., 2012). The putative
inﬂammation-associated reduction in dopamine concentration may also
be a result of an inﬂammation-induced breakdown of tetrahydro-
biopterin (BH4), an enzyme co-factor for tyrosine hydroxylase, which
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thesis (Capuron and Miller, 2011).
Consistent with the data suggesting an inﬂammation-related in-
crease in 5-HTT activity and a decrease in tyrosinehydroxylase function,
LPS-induced tumor necrosis factor alpha (TNF) expression was almost
completely inhibited by the MAO-A/B inhibitor, phenelzine, in rodents
(Ekuni et al., 2009) while the MAO-A inhibitor moclobemide was
demonstrated to inhibit the production of TNF and IL8 in healthy volun-
teers as well as to enhance the LPS-stimulated production of the anti-
inﬂammatory cytokine IL10 (Lin et al., 2000). Conceivably therefore, in-
ﬂammation may partly account for the changes in 5-HTT, DAT, and
MAO-A function reported in PET studies of depression.2
The relationship between inﬂammation and glucocorticoid signaling
is complex (Miller et al., 1999) and beyond the scope of this review.
Nevertheless, inﬂammation may impact neuroreceptor function via its
effects on the endocrine system. Regardless of the nature of the rela-
tionship between inﬂammation and endocrine dysregulation, stress,
which is associated with mood disorders, is known to impact glucocor-
ticoid signaling.
As reviewed above, stress-induced secretion of corticosteroids
may lead to the downregulation of 5-HT1A postsynaptic receptor ex-
pression and possibly also to 5-HT1A autoreceptor function in the
raphe. In contrast, 5-HT2A receptors may be upregulated by glucocor-
ticoid hypersecretion, facilitating the secretion of cortisol releasing
factor (CRF) during stress and contributing to the chronic elevation
of circulating cortisol levels. Consistent with reports of increased
MAO-A binding in depression, elderly rats administered dexametha-
sone were reported to show a 300% increase in MAO-A density in
the brain (Slotkin et al., 1998). Similarly, increased serotonergic neuro-
transmission in response to stress and/or depression-related inﬂamma-
tion may result in a chronic increase in 5-HTT function, contributing to
decreased serotonergic signaling at the postsynaptic 5-HT1A receptor.
Conceivably, the anhedonia and motivational deﬁcits characteristic of
depression may result from decreased dopaminergic signaling in the
ventral striatum concurrent with reduced tyrosine hydroxylase, DAT
and/or D1 receptor function.Conclusion and future directions
PET neuroreceptor imaging has revolutionized our understanding
of psychiatric illness by allowing for the in vivo study of speciﬁc pro-
teins in the brain. The current focus on serotonin and dopamine re-
ceptor and transporter proteins is likely to expand in the future as
new radioligands are developed. Multi-modal imaging studies that
combine fMRI and PET data may offer new insights into the patho-
physiology of mood disorders. This approach has been implemented
successfully in healthy individuals (Fisher et al., 2006, 2009; Kienast
et al., 2008; Rhodes et al., 2007; Takahashi et al., 2010).
The results obtained for a particular receptor also may be affected
by the activity of an interacting receptor. For example, Fisher et al.
(2011) reported that PFC 5-HT1A binding moderates the effect of
5-HT2A binding on the hemodynamic response of the amygdala to
threatening faces. Thus future studies should attempt to obtain data
from multiple receptors in the same cohort of volunteers. Studies
that integrate receptor function with endocrine or immune data
may also produce important new leads. Finally, the need exists for
longitudinal PET studies which would allow changes in neuroreceptor
function to be coupled to clinical state. Identiﬁcation of the genetic
correlates of receptor function in the context of PET imaging is also
important but acquiring the necessary statistical power is a challenge
given the expense and invasiveness of PET.2 We note parenthetically that BMI, which has been shown to impact 5-HT2A recep-
tor binding and 5-HTT binding, correlates positively with inﬂammation.Acknowledgments
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